During every earnings season, investors should re-assess their current holdings and consider which sectors are presenting the most promise. Investors don’t need to be scientists to determine good buying opportunities in biotech, healthcare or pharmaceutical stocks.

In the world of pharmaceutical and healthcare companies, these two are standing out as solid buys.

Allergan (AGN)

Allergan (AGN) has been at the center of a takeover battle between some of the largest players in biotech — including Valeant pharma and our holding Actavis (ACT).

As for Valeant Pharmaceuticals, it is fixated on trying to acquire Allergan in a hostile takeover, having raised its bid several times. Valeant Pharmaceuticals clearly wants to dominate the cosmetic surgery market, where future price increases are not insurance-related. As for Allergan, it has little interest in being acquired by Valeant Pharma. Allergan is looking to acquire Salix Pharmaceuticals (SLXP); the merged company would throw a wrench in Valeant Pharma’s hostile takeover plans.

Nonetheless, there’s no denying that Allergan is an attractive takeover candidate. Allergan is best known for producing Botox, the world’s top-selling minimally invasive aesthetic medical treatment, and the only product of its kind approved to treat crow’s feet lines. Annual Botox sales alone are expected to reach $3.15 billion by 2018.

And there’s much more to Allergan than Botox. Allergan is the world leader in dermal fillers. Allergan is also the second-largest ophthalmic (eye care) company — this business accounts for nearly half of Allergan’s worldwide revenues. Allergan’s ophthalmic products treat everything from dry eye to glaucoma to retinal disease. Allergan also offers a range of medical devices used in cosmetic and reconstructive surgery.

All of this translates into stunning earnings potential. Allergan recently raised its third-quarter earnings guidance to a range of $1.76 per share to $1.78 per share. This is significantly higher than the company’s previous guidance of $1.44 per share to $1.47 per share. The analyst community is also very bullish about Allergan for the most recent quarter. In the past three months, analysts have raised their consensus earnings estimate from $1.45 to $1.65 per share.

CVS Health (CVS)

My next recommendation comes just in time for flu season. CVS Health (CVS) provides integrated pharmacy health care services in the U.S. CVS is best known for operating over 7,700 CVS pharmacies and Longs Drug stores throughout the U.S. CVS pharmacies are stocked up with prescription and over-the-counter drugs, beauty products, seasonal merchandise, greeting cards and a limited selection of convenience foods.

And CVS Health’s retail division is just one out of four main businesses. CVS Caremark offers pharmacy benefit management (PBM) services, which includes mail service pharmacy offerings, plan design and Medicare Part D services. CVS Caremark serves employers, health insurance companies, unions and government employee groups.

CVS MinuteClinic is the country’s leading retail medical clinic provider, with more than 900 locations across 29 states. MinuteClinic locations are staffed by nurse practitioners and physician assistants to treat common illnesses, skin conditions and injuries, as well as conduct wellness screenings and administer vaccinations. Finally, CVS operates a specialty pharmacy division that offers services for patients with rare or complex conditions.

While most of us have known this company as CVS Caremark, it recently changed its name to CVS Health Corp. as part of a larger rebranding initiative. True to its new name, in September, CVS also stopped selling cigarettes. While this will weigh on CVS’ top line in the near-term, CVS’ long-term prospects are looking great.

For starters, because CVS and prescription benefit manager Caremark combined years ago, CVS is less vulnerable to reimbursement pressures. This places it head and shoulders above competitors like Walgreens, which had a falling out with Express Scripts in 2012. CVS is also benefitting from its recent acquisition of Coram, a provider of specialty infusion services. Through its MinuteClinic locations and specialty drug businesses, CVS is able to offer patients health care services at much cheaper prices than what’s charged at hospitals. And all of CVS Health’s businesses benefit from the health care industry’s preference for pills (over procedures), which are cheaper and eliminate the risk of infection.

So, CVS has a lot going for it, and this makes me very bullish for CVS. CVS stock is a good “buy.”

Louis Navellier is a renowned growth investor. He is the editor of five investing newsletters: Blue Chip Growth, Emerging Growth, Ultimate Growth, Family Trust and Platinum Growth. His most popular service, Blue Chip Growth, has a track record of beating the market 3:1 over the last 14 years. He uses a combination of quantitative and fundamental analysis to identify market-beating stocks. Mr. Navellier has made his proven formula accessible to investors via his free, online stock rating tool, PortfolioGrader.com. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters.